Loading stock data…
ELTX
$14.20+0.65 (+4.80%)
After Hours$14.20+0.00 (+0.00%)· Last close Jun 9
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Elicio Therapeutics, Inc. in the Healthcare sector is trading at $14.20 with a market capitalization of $239M. Wall Street consensus targets $17.50 (2 analysts), implying a +23.2% move over the next 12 months. The stock is currently near its 52-week high of $14.97, remaining 41.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$14.20
Potential Downside
0%
Whystock Fair Value$14.20
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II cl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$239.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
2796.45%
Volume
Today's trading volume
124,784
Recent News
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
Here is how Aura Biosciences, Inc. (AURA) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in Elicio Therapeutics (ELTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Elicio Therapeutics: Q4 Earnings Snapshot
BOSTON (AP) — Elicio Therapeutics, Inc. ELTX) on Thursday reported a loss of $7.7 million in its fourth quarter. The Boston-based company said it had a loss of 49 cents per share.
While insiders own 33% of Elicio Therapeutics, Inc. (NASDAQ:ELTX), individual investors are its largest shareholders with 55% ownership
Key Insights Elicio Therapeutics' significant individual investors ownership suggests that the key decisions are...
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why
Elicio Therapeutics (ELTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).